Literature DB >> 476683

Cytotoxic effects of chemotherapeutic drugs on mouse testis cells.

C C Lu, M L Meistrich.   

Abstract

Studies of testicular cell killing in mice by several chemotherapeutic drugs have been performed to EVALUATE THE HARMFUL EFFECTS OF ONCOLYTIC AGENTS ON REPRODUCTION. Seven drugs, Adriamycin, 1-beta-D-arabinofuranosylcytosine, bleomycin, cyclophosphamide, hydroxyurea, vinblastine, and vincristine, given as single injections, were cytotoxic to differentiated spermatogonia. Adriamycin was also highly effective in killing stem cells. The other drugs produced little or no stem cell loss even at doses toxic to the animals. Negligible killing of spermatocytes and spermatids was noted at any dose level. The results demonstrated that oncolytic agents preferntially killed cells at specific stages of the spermatogenic pathway in mice at doses within the clinical range for humans.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 476683

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  29 in total

1.  Green tea extracts attenuate doxorubicin-induced spermatogenic disorders in conjunction with higher telomerase activity in mice.

Authors:  Kenji Sato; Kou Sueoka; Reiko Tanigaki; Hiroto Tajima; Akira Nakabayashi; Yasunori Yoshimura; Yoshihiko Hosoi
Journal:  J Assist Reprod Genet       Date:  2010-05-27       Impact factor: 3.412

2.  Effects of multiple doses of cyclophosphamide on mouse testes: accessing the germ cells lost, and the functional damage of stem cells.

Authors:  Ana Luiza Drumond; Connie C Weng; Gensheng Wang; Helio Chiarini-Garcia; Leticia Eras-Garcia; Marvin L Meistrich
Journal:  Reprod Toxicol       Date:  2011-10-07       Impact factor: 3.143

Review 3.  Effects of chemotherapy and radiotherapy on spermatogenesis in humans.

Authors:  Marvin L Meistrich
Journal:  Fertil Steril       Date:  2013-09-04       Impact factor: 7.329

4.  Follicle-stimulating hormone enhances recovery from low-dose doxorubicin-induced spermatogenic disorders in mice.

Authors:  Jun Hagiuda; Hiromichi Ishikawa; Satoru Kaneko; Masako Okazaki; Mototsugu Oya; Ken Nakagawa
Journal:  J Assist Reprod Genet       Date:  2015-04-16       Impact factor: 3.412

Review 5.  Beyond the mouse monopoly: studying the male germ line in domestic animal models.

Authors:  Raquel González; Ina Dobrinski
Journal:  ILAR J       Date:  2015

6.  Granulocyte colony-stimulating factor prevents loss of spermatogenesis after sterilizing busulfan chemotherapy.

Authors:  Roberto Benavides-Garcia; Rose Joachim; Nancy A Pina; Kazadi N Mutoji; Matthew A Reilly; Brian P Hermann
Journal:  Fertil Steril       Date:  2014-11-05       Impact factor: 7.329

7.  PAX7 expression defines germline stem cells in the adult testis.

Authors:  Gina M Aloisio; Yuji Nakada; Hatice D Saatcioglu; Christopher G Peña; Michael D Baker; Edward D Tarnawa; Jishnu Mukherjee; Hema Manjunath; Abhijit Bugde; Anita L Sengupta; James F Amatruda; Ileana Cuevas; F Kent Hamra; Diego H Castrillon
Journal:  J Clin Invest       Date:  2014-08-18       Impact factor: 14.808

8.  Testicular morphology and cauda epididymal sperm reserves of male rats exposed to Nigerian Qua Iboe Brent crude oil.

Authors:  I Reginald Obidike; Igwebuike U Maduabuchi; Shoyinka S V Olumuyiwa
Journal:  J Vet Sci       Date:  2007-03       Impact factor: 1.672

9.  Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.

Authors:  Kea M Jones; Mohammad S Niaz; Cynthia M Brooks; Shannon I Roberson; Maria P Aguinaga; Edward R Hills; Valerie Montgomery Rice; Phillip Bourne; Donald Bruce; Anthony E Archibong
Journal:  Int J Environ Res Public Health       Date:  2009-03-16       Impact factor: 3.390

10.  Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status.

Authors:  Vanessa Vendramini; Estela Sasso-Cerri; Sandra M Miraglia
Journal:  Reprod Biol Endocrinol       Date:  2010-01-10       Impact factor: 5.211
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.